Detalhe da pesquisa
1.
Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V.
Mol Cell Proteomics
; 18(4): 622-641, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30617155
2.
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
Mol Cell Proteomics
; 16(5): 891-910, 2017 05.
Artigo
Inglês
| MEDLINE | ID: mdl-28331001
3.
Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
Proteomics
; 15(2-3): 340-55, 2015 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-25404012
4.
Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance.
Cancers (Basel)
; 15(8)2023 Apr 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37190191
5.
Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors.
Mol Cancer Ther
; 21(7): 1195-1206, 2022 07 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35499461
6.
Alterations in HLA Class I-Presented Immunopeptidome and Class I-Interactome upon Osimertinib Resistance in EGFR Mutant Lung Adenocarcinoma.
Cancers (Basel)
; 13(19)2021 Oct 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34638461
7.
SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma.
Oncogene
; 40(18): 3331-3346, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33850265
8.
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.
Cell Rep Med
; 1(1)2020 04 21.
Artigo
Inglês
| MEDLINE | ID: mdl-32483558
9.
APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors.
Cell Rep
; 26(10): 2651-2666.e6, 2019 03 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30840888
10.
EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.
Oncotarget
; 7(34): 54137-54156, 2016 Aug 23.
Artigo
Inglês
| MEDLINE | ID: mdl-27494838
11.
Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.
Cold Spring Harb Mol Case Stud
; 2(6): a001263, 2016 11.
Artigo
Inglês
| MEDLINE | ID: mdl-27900369
12.
Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.
Cancer Discov
; 5(5): 534-49, 2015 May.
Artigo
Inglês
| MEDLINE | ID: mdl-25735773